Immutep’s Eftilagimod Alfa Data to Feature at ASCO 2026
Event summary
- Immutep’s abstract on eftilagimod alfa accepted for ASCO 2026 poster presentation.
- Poster highlights lymphocyte activation and survival outcomes in metastatic cancer patients.
- Data derived from multiple late-stage cancer studies, excluding TACTI-004 trial results.
- Presentation scheduled for May 30, 2026, during the Developmental Therapeutics—Immunotherapy session.
The big picture
Immutep’s ASCO presentation comes as the immunotherapy sector continues to evolve, with increasing focus on antigen-presenting cell (APC) activators. The data could position eftilagimod alfa as a key player in the treatment of metastatic cancers, particularly if survival outcomes are compelling. The exclusion of TACTI-004 data suggests ongoing refinement of the clinical profile, which will be critical for regulatory and commercial strategies.
What we're watching
- Clinical Validation
- Whether the ASCO presentation will reinforce eftilagimod alfa’s mechanism of action and its potential as a therapeutic option.
- Regulatory Pathway
- The pace at which Immutep advances eftilagimod alfa through late-stage trials following the ASCO data.
- Market Differentiation
- How the data compares to competing immunotherapies in the metastatic cancer space.
Related topics